Prostate Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have been advised to consider a prostate biopsy based on standard medical guidelines
- You have had a recent PSA blood test showing a result below 100 ng/ml (a measure of a protein linked to prostate health)
- Your prostate concern appears to be a new, primary issue with no history of other cancers
- You have had a high-quality prostate MRI scan (a type of detailed imaging) that shows a score of 3 or higher on a standard rating scale used by radiologists
- You fully understand what the study involves and are willing to sign a consent form agreeing to take part
Who may not be able to join:
- You are unable to have an MRI scan for medical reasons (for example, having certain metal implants)
- Your MRI scan gave a low suspicion score (rated 1 or 2 on the radiologist's scale)
- You have a medical reason that prevents you from having a prostate biopsy, or you do not wish to have one
- Your MRI scan showed signs that the cancer may have spread to lymph nodes or bones
- You have previously had surgery on your prostate
- You are not willing to sign the consent form to participate in the study
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Jun Xiao, The First Affiliated Hospital of USTC
Phone: 15840256553
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Evaluate whether ADC values can improve the diagnostic capacity of bpMRI for clinically significant prostate cancer (csPCa) (Gleason score ≥ 3+4, ISUP grade ≥ 2) in patients with PI-RADS 3-5.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 5 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.